BCR-ABL rearrangements in children with Philadelphia chromosome- positive chronic myelogenous leukemia [PDF]
Blood, 1991 Abstract Leukemia cells from adults with Philadelphia (Ph1)-chromosome positive chronic myelogenous leukemia (CML) have a characteristic molecular rearrangement between the BCR and ABL genes whereby major breakpoint cluster region (Mbcr) exons 2 or 3 are joined to ABL exon II.
I, Aurer, A, Butturini, R P, Gale
openaire +3 more sources
New type of Bcr/Abl junction in Philadelphia chromosome-positive chronic myelogenous leukemia [PDF]
Blood, 1990 A new and rare type of Bcr/Abl junction between exon C3 of the 3′ portion of the Bcr gene and Abl exon 2 has been identified in the leukemic cells of two Ph1-positive chronic myelogenous leukemia patients in chronic phase. This is the fourth type of Bcr/Abl junction so far identified in Ph1-positive hematologic malignancies and is a consequence of an ...
SAGLIO, Giuseppe +8 more
openaire +4 more sources
Proliferating status of peripheral blood progenitor cells from patients with BCR/ABL-positive chronic myelogenous leukemia [PDF]
Leukemia, 2001 To investigate the mechanisms behind the leukemic expansion of BCR/ABL-positive chronic myelogenous leukemia (CML), we examined the cell cycle status of hematopoietic progenitor cells from peripheral blood (PB) and bone marrow (BM) of 37 patients with newly diagnosed BCR/ABL-positive CML.
A, Krämer +4 more
openaire +2 more sources
The Relationship Between the Type ofbcr-ablHybrid Messenger RNA and Thrombopoiesis in Philadelphia-Positive Chronic Myelogenous Leukemia [PDF]
Leukemia & Lymphoma, 1993 Formation of the Philadelphia (Ph1) chromosome, which contains the hybrid bcr-abl gene, is thought to be the initial event in chronic myelogenous leukemia (CML). The positions of the breakpoint within the breakpoint cluster region (bcr) on the bcr-abl gene in 22 chronic-phase cases of Ph1-positive CML were determined using conventional Southern blots ...
K, Inokuchi, T, Nomura
+8 more sources
Targeting BCR-Abl in the treatment of Philadelphia-chromosome positive chronic myelogenous leukemia
Pharmacological Research, 2022 Chronic myelogenous leukemia (CML) is an indolent malignant hematological disease that accounts for about 15% of all cases of leukemia. This disorder results from the formation of the Philadelphia chromosome that involves a reciprocal translocation that produces a lengthened chromosome 9 and shortened chromosome 22 - the Philadelphia chromosome.
openaire +2 more sources
Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib [PDF]
Blood Cancer Journal, 2015 Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL -positive chronic myelogenous leukemia treated with ruxolitinib and ...
Zhou, A +4 more
openaire +1 more source
T-Lymphoblastic Leukemia With t(9;22): Blast Phase of Chronic Myelogenous Leukemia or BCR-ABL- Positive T-Acute Lymphoblastic Leukemia? [PDF]
American Journal of Clinical Pathology, 2012 T-acute lymphoblastic leukemia/lymphoma (T-ALL) as chronic myelogenous leukemia blast phase (CML-BP) is rare. BCR-ABL–positive T-ALL is extremely rare. In patients without previous/concurrent history of CML, it is difficult to differentiate these 2 entities. Herein we report 3 cases of T-ALL with t(9;22) and review the literature.
Jie Xu, Shaoying Li
openaire +1 more source
A Case with Coexistence of Major and Minor BCR/ABL Fusion Transcript at Lymphoblastic Crisis of Chronic Myelogenous Leukemia in Patients with Major BCR/ ABL Positivity during Chronic Phase [PDF]
Annals of Laboratory Medicine, 2013 Dear Editor CML is characterized by the clonal expansion of bone marrow hematopoietic cells and is associated with the Philadelphia chromosome [1]. The accelerated phase of CML, which is also known as the blast crisis phase, occurs in patients as the disease progresses.
Park, Sang Hyuk +5 more
openaire +1 more source
Epigenetic dysregulation in chronic myeloid leukaemia: A myriad of mechanisms and therapeutic options [PDF]
, 2018 The onset of global epigenetic changes in chromatin that drive tumor proliferation and heterogeneity is a hallmark of many forms cancer. Identifying the epigenetic mechanisms that govern these changes and developing therapeutic approaches to modulate ...
Koschmieder, Steffen, Vetrie, David
core +1 more source
Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia
Molecular Cancer, 2007 Background Ph-positive leukemias are caused by the aberrant fusion of the BCR and ABL genes. Nilotinib is a selective Bcr/Abl tyrosine kinase inhibitor related to imatinib, which is widely used to treat chronic myelogenous leukemia.
Groffen John +7 more
doaj +1 more source